A placebo- and positive-controlled study of the electrophysiological effects of a single 10 microg dose of exenatide on the 12-lead electrocardiogram QT interval in healthy subjects

Trial Profile

A placebo- and positive-controlled study of the electrophysiological effects of a single 10 microg dose of exenatide on the 12-lead electrocardiogram QT interval in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Exenatide (Primary) ; Moxifloxacin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 01 Oct 2008 Actual end date changed from 1 Aug 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top